Publications
Predictive for Dose-Intense Chemotherapy Benefit
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer
Metzger Filho O, et al. J Clin Oncol. 2025 Jan 2:JCO2401875. doi: 10.1200/JCO-24-01875. PMID: 39746162.
Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial.
Martin M, et al. Clin Cancer Res (2026) 32 (17): 3870–3879. https://doi.org/10.1158/1078-0432.CCR-26-0177
Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial.
Penault-Llorca F, et al. The Breast, Volume 89, 2026, 104894, ISSN 0960-9776, https://doi.org/10.1016/j.breast.2026.104894
Predictive for Extended Endocrine therapy Benefit
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Du L, Yau C, et al. Ann Oncol. 2021;32(5):642-51. DOI: 10.1016/j.annonc.2021.02.011. PMID: 33617937
Mamounas EP, et al. Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial.
San Antonio Breast Cancer Symposium 2025. Abstract GS3-05.
Prognostic for Long Term Outcomes
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
Du L, Yau C, et al. Ann Oncol. 2021;32(5):642-51. Epub 2021/02/23. doi: 10.1016/j.annonc.2021.02.011. PMID: 33617937
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
Speers CW, et al. J Clin Oncol. 2023 Jan 17:JCO2201499. doi: 10.1200/JCO.22.01499. PMID: 36649570.
Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
Suman VJ, Du L, et al. Clin Cancer Res. 2022 Aug 2;28(15):3287-3295. doi: 10.1158/1078-0432.CCR-22-0068. PMID: 35653124
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score® in node-positive breast cancer: independent validation in the PACS-01 trial. 2024 American Society of Clinical Oncology Annual Meeting, Chicago, IL. May 31-Jun 4, 2024
Penault-Llorca F, et al. J Clin Oncol 42, 2024 (suppl 16; abstr 565), doi: 10.1200/JCO.2024.42.16_suppl.565
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13)
Metzger O, et al. 2024 American Society of Clinical Oncology Annual Meeting, Chicago, IL. May 31-Jun 4, 2024. J Clin Oncol 42, 2024 (suppl 16; abstr 538), DOI: 10.1200/JCO.2024.42.16_suppl.538
Technical Validation Studies
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
Symmans WF, et al. J Clin Oncol 28(27):4111-9, 9/2010. doi: 10.1200/JCO.2010.28.4273 PMID: 20697068
Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue
Lau R, Du L, et al. Clin Chem. 2020 Jul 1;66(7):934-945. doi: 10.1093/clinchem/hvaa105. PMID: 32613237
Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer
Bossuyt V, et al. Clin Chem. 2021;67(9):1240-8. Epub 2021/08/11. doi: 10.1093/clinchem/hvab068. PMID: 34374711
SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.
Sinn, B.V., Fu, C., Lau, R. et al. npj Breast Cancer 5, 16 (2019). DOI: 10.1038/s41523-019-0111-0 PMID: 31231679
Contact Us
Want to learn more about the Endocrine Activity Index (EAI) or Delphi Diagnostics?